About 1 000 reports

  • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
  • 6.3.3 MARKET SIZE

A prime example of this is the emergence of immunotherapies and PD-##/ PD-L## targeted agents.

  • Targeted Therapy
  • Market Size
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • STAGE OF DEVELOPMENT PRECLINICAL IND/CTA-FILED PHASE I PHASE II PHASE III PRE-REGISTRATION
  • Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type,

Immunotherapy, which includes chemotherapy, has revolutionized cancer treatment.

  • Targeted Therapy
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG
  • SALES FORECAST BY CLASS FOR PROSTATE CANCER IN THE US IN 2018 AND 2028
  • GLOBAL SALES FORECAST BY COUNTRY FOR PROSTATE CANCER IN 2018 AND 2028

ONE OF ITS MOST SUCCESSFUL DRUGS TO DATE IS THE BLOCKBUSTER ANTI-PD-## IMMUNOTHERAPY KEYTRUDA.

  • Targeted Therapy
  • East Asia
  • United States
  • Forecast
  • Pfizer Inc.
  • DEMAND
  • Chapter IV

The auto exports exceeded over ## million each year.

  • Targeted Therapy
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

Global Tumor-specific Antigen Market Chapter ## Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analyst’s Credentials Chapter ## Summary and Highlights Chapter ## Market and Technology Background Market O

  • Medical Biotechnology
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Forecast
  • CURRENT TRIALS OF PARP/IO COMBINATIONS (2017)
  • 4.1 GROWTH DRIVERS

Rucaparib is a top-of-the-line pharmaceutical preparation for the repair polymerase of DNA polymerase-## (PARP-##) poly-ADP.

  • Targeted Therapy
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

APPENDIX ##: TABULATED DATA ##.

  • Targeted Therapy
  • Therapy
  • United States
  • World
  • Market Size

TOPICAL IMMUNOTHERAPY AND VASODILATORS: TOPICAL IMMUNOTHERAPY IS ONE OF THE BEST TREATMENTS SO FAR FOR SEVERE AND REFRACTORY ALOPECIA AREATA.

  • Targeted Therapy
  • World
  • Forecast
  • Allergan plc
  • Galderma S.A.
  • Bavencio
  • 9.2 INNOVATIVE EARLY-STAGE APPROACHES

" Antiangiogenic therapy and immunotherapy, that' s a great mix again because it would release more antigens and might augment to make the immunotherapy more effective.

  • Targeted Therapy
  • United States
  • Forecast
  • AstraZeneca PLC
  • Roche Group
  • 5.1.2 FAILURE RATE BY PHASE AND MOLECULE TYPE
  • B) Phase II

Nivolumab as Programmed Death-## (PD-##) Inhibitor for Targeted Immunotherapy in Tumor.

  • Chemotherapy
  • Targeted Therapy
  • Therapy
  • Market Size
  • Merck & Co., Inc.
  • SALES FOR CRC IN THE 5EU, BY DRUG CLASS, 2015-2025
  • US CRC MARKET DRIVERS AND BARRIERS, 2016

US KEY OPINION LEADER CURRENTLY, THERE IS ONLY ONE LATE-STAGE IMMUNOTHERAPY IN THE PIPELINE THAT TARGETS MSS PATIENTS, ROCHE' S TECENTRIQ.

  • Targeted Therapy
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • Taiho Pharmaceutical Co., Ltd.

N. (2016) ' UPDATE ON PSORIASIS IMMUNOPATHOGENESIS AND TARGETED IMMUNOTHERAPY', SEMINARS IN IMMUNOPATHOLOGY, PP. ##-##.

  • Targeted Therapy
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

Topical immunotherapies are another treatment option for extensive alopecia.

  • Targeted Therapy
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.
  • SHOWS A SUMMARY OF NOVEL IMMUNOTHERAPIES IN EARLY-STAGE DEVELOPMENT.
  • DRUGS IN DEVELOPMENT, 2017

JOURNAL OF IMMUNOTHERAPY; ##(##): ##-##.

  • Targeted Therapy
  • Australia
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • Global Biologics Market, 2017, International Collaborations In Innovative Biologics

THESE INCLUDE IMMUNOTHERAPIES, ANTIBODY-DRUG CONJUGATES (ADCS), BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES (ABS) AND MONOCLONAL ABS (MABS).

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • RECENT DEVELOPMENTS
  • GLOBAL CANCER IMMUNOTHERAPIES MARKET BY TYPE OF CANCER IMMUNOTHERAPIES 2015- 2020 ($ BILLIONS)

In May 2015, the company and Merck expanded their collaboration to evaluate the efficacy and safety of T-VAC (its investigational oncolytic immunotherapy) in combination with Keytruda (Merck' s anti-PD-## therapy), in Phase ##, open-label trial of people with recurrent o

  • Targeted Therapy
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Global Biologics Market, 2017, International Collaborations In Innovative Biologics

THESE INCLUDE IMMUNOTHERAPIES, ANTIBODY-DRUG CONJUGATES (ADCS), BISPECIFIC T-CELL ENGAGER (BITE) ANTIBODIES (ABS) AND MONOCLONAL ABS (MABS).

  • Targeted Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • 5.1.2 FAILURE RATE BY PHASE AND MOLECULE TYPE
  • Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rates by Molecule

Nanda on Immunotherapy in Metastatic TNBC.

  • Cancer
  • Targeted Therapy
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

Global PARP Inhibitors Cancer Therapy Market, Price, Dosage & Clinical Pipeline Outlook 2023 ##.

  • Targeted Therapy
  • Therapy
  • World
  • Oncology Drugs Market Share by Launch; 1996-2007
  • d. Prompt Diagnosis

Combination of approved immunotherapies with new in-research immunotherapies has resulted in improved response rates for patients with RCC.

  • Targeted Therapy
  • Argos Therapeutics, Inc.
  • AstraZeneca PLC
  • AVEO Oncology
  • Bristol-Myers Squibb Company
  • 3 Marketed Products
  • NSCLC Therapeutics Market, APAC, Ipilimumab Forecast ($m), 2019-2023

PLoS One; ##(##): e## Lee P, et al. (2012).

  • Targeted Therapy
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novartis AG
  • Roche Group

The chapter is organized by specific monoclonal antibody technology type in focus.

  • Monoclonal Antibody
  • Pharmaceutical
  • Targeted Therapy
  • United States
  • Demand

" When it comes to immunotherapy, I look to two distinct classes: active vaccines and passive vaccines.

  • United States
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • Roche Group

The chapter is organized by specific Cancer monoclonal antibody technology type in focus.

  • Cancer
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • Demand

The market-leading drug in 2017 was Rituxan, which is the SOC therapy that forms the backbone of chemo-immunotherapy regimens across B-cell NHL.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • United States
  • Forecast
  • FIRST ANTI-CD20 MAB TO ENTER THE MS MARKET TO COMPETE WITH OCREVUS
  • NOVARTIS' OFATUMUMAB WILL COMPETE AGAINST BLOCKBUSTER OCREVUS, WITH ITS SC FORMULATION CONFERRING AN ADVANTAGE OVER OCREVUS' IV ADMINISTRATION.

Which I' ve heard, I think, from Novartis, they think it can be self-administered, which is somewhat concerning to me because of the potential risks associated with such profound immunotherapy being in the hands of patients.

  • Targeted Therapy
  • United States
  • Forecast
  • Novartis AG
  • TG Therapeutics, Inc.
  • POTENTIAL TREATMENT OPTIONS
  • GROWING STRATEGIC ACQUISITIONS

Cellular therapy could be one of the specific immunotherapy approaches to treating myasthenia gravis.

  • Targeted Therapy
  • Alexion Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Flamel Technologies S.A.
  • Pfizer Inc.

Morgan Table ##: Chemical Drugs vs.

  • Targeted Therapy
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • anti-CS1 antibody, elotuzumab
  • ONCOLOGY, GLOBAL, CO-DEVELOPMENT DEALS BY MOLECULE TYPE AND MECHANISM OF

Novartis AG Karolinska Institutet Phase I RG-## HKT-## Phase I Phase I Phase I Cellular Immunotherapy to Target NY-ESO- ## for Metastatic Melanoma Cellular Immunotherapy to Target NY-ESO- ## for Oncology Shenzhen Second People' s Hospital Phase I Cellular

  • Targeted Therapy
  • AstraZeneca PLC
  • Celgene Corporation
  • Novartis AG
  • Pfizer Inc.
  • 2.5 LATE-STAGE PIPELINE DRUGS ENTERING THE MS MARKET WILL BE A KEY DRIVER OF

AUTOIMMUNE CONCEPTS OF MULTIPLE SCLEROSIS AS A BASIS FOR selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

  • Targeted Therapy
  • United States
  • Forecast
  • Biogen Idec Inc.
  • Novartis AG